Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Discussion Principal findings We modelled the effects and costs of widespread use of SGLT2is and GLP-1 RAs in the total and secondary prevention populations with type 2 diabetes in Australia, considering only their benefits on major cardiovascular and kidney outcomes, from 2020 to 2040
That growth brings a new imperative: GLP1 strategies must be designed to scale
As GLP-1 therapies, these drugs control blood sugar levels and help people eat less, which makes them highly effective treatments for both Type 2 diabetes and obesity
doi:10.1155/2015/648108 Philp D, Goldstein AL, Kleinman HK
US$ 26.94
US$ 28.37
US$ 25.25
US$ 24.73
US$ 24.80
US$ 22.16
US$ 27.92
US$ 21.28
